Merck Animal Health, a division of Merck & Co., announced the FDA’s approval of an expanded indication for Bravecto Chews for Dogs. The new indication treats and controls Asian longhorned ticks, which are an invasive Ixodid species located across more than one-third of the U.S.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Another Feather on Merck’s Cap: Keytruda’s NSCLC Treatment Gets Another Indication
- Merck to stop Phase 3 KEYNOTE-991 trial
- Merck reports ‘positive’ results from Phase 3 KEYNOTE-966 trial
- Merck picks Perceiv AI for inaugural Digital Sciences Studio cohort
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
